Search Results

• • 8 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling

  Authors:Pernilla Roswall, Matteo Bocci, Michael Bartoschek, Hong Li, Glen Kristiansen, Sara Jansson, et al.From:Nature Medicine (Vol. 24, Issue 4) Peer-Reviewed

  Apr. 201812,781 words Report 1600LBreast tumors of the basal-like, hormone receptor-negative subtype remain an unmet clinical challenge, as there is high rate of recurrence and poor survival in patients following treatment. Coevolution of the malignant...

• The Prognostic Significance of Wnt-5a Expression in Primary Breast Cancer Is Extended to Premenopausal Women

  Authors:Janna Sand-Dejmek, Roy Ehrnstrom, Pontus Berglund, Tommy Andersson, and Lisa RydenFrom:PLoS ONE (Vol. 8, Issue 8) Peer-Reviewed

  Aug. 22, 20135,766 words Article 1470LAuthor(s): Janna Sand-Dejmek 1,2,*, Roy Ehrnström 3, Pontus Berglund 1, Tommy Andersson 1, Lisa Ryden 4 Introduction Breast cancer is a heterogenous disease. The heterogeneity of the disease affects not only the...

• Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients

  Authors:Caroline Bergenfelz, Anna-Maria Larsson, Kristoffer von Stedingk, Sofia Gruvberger-Saal, Kristina Aaltonen, Sara Jansson, et al.From:PLoS ONE (Vol. 10, Issue 5) Peer-Reviewed

  May 20, 201510,428 words Article 1500LMyeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells, which increase in cancer patients. The molecular mechanism behind their generation and function is unclear. Whereas granulocytic-MDSCs...

• The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFR[alpha], Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer

  Authors:Sara Jansson, Par-Ola Bendahl, Dorthe Aamand Grabau, Anna-Karin Falck, Marten Ferno, Kristina Aaltonen, et al.From:PLoS ONE (Vol. 9, Issue 7) Peer-Reviewed

  July 15, 20146,300 words Article 1530LBackground Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer with poor prognosis and no targeted therapy available. Receptor tyrosine kinases (RTKs) are emerging targets in anticancer...

• Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.

  Authors:Julia Tutzauer, Martin Sjöström, Pär-Ola Bendahl, Lisa Rydén, Mårten Fernö, L. M. Fredrik Leeb-Lundberg, et al.From:PLoS ONE (Vol. 15, Issue 4) Peer-Reviewed

  Apr. 17, 20207,842 words Article 1450LBackground G protein-coupled estrogen receptor (GPER), or G protein-coupled receptor 30 (GPR30), is reported to mediate non-genomic estrogen signaling. GPR30 associates with breast cancer (BC) outcome and may...

• Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer

  Authors:Susann Busch, Lisa Ryden, Olle Stal, Karin Jirstrom, and Goran LandbergFrom:PLoS ONE (Vol. 7, Issue 9) Peer-Reviewed

  Sept. 24, 20126,253 words Report 1560LAuthor(s): Susann Busch 1 , Lisa Rydén 2 , Olle Stål 3 , Karin Jirström 4 , Göran Landberg 1 , 4 , 5 , * Introduction The administration of the anti-estrogen tamoxifen is an adjuvant endocrine therapy for patients...

• Tumor tissue protein signatures reflect histological grade of breast cancer

  Authors:Petter Skoog, Mattias Ohlsson, Marten Ferno, Lisa Ryden, Carl A. K. Borrebaeck, and Christer WingrenFrom:PLoS ONE (Vol. 12, Issue 6) Peer-Reviewed

  June 26, 20178,622 words Report 1510LHistological grade is one of the most commonly used prognostic factors for patients diagnosed with breast cancer. However, conventional grading has proven technically challenging, and up to 60% of the tumors are...

• Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer

  Authors:Sara Alkner, Par-Ola Bendahl, Anna Ehinger, Kristina Lovgren, Lisa Ryden, and Marten FernoFrom:PLoS ONE (Vol. 11, Issue 3) Peer-Reviewed

  Mar. 9, 20165,919 words Report 1380LAim The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance. We hereby...